TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.
EBioMedicine
; 2(8): 825-30, 2015 Aug.
Article
de En
| MEDLINE
| ID: mdl-26425688
Mots clés
5FU, 5-fluorouracil; ABCSG, Austrian Breast and Colorectal Cancer Study Group; Adjuvant 5-fluorouracil; CI, confidence intervals; FFPE, formalin-fixed paraffin-embedded; HR, hazard ratios; INF, interferon; LEV, levamisole; Predictive biomarker; Stage III colon cancer; TP53; Varying treatment efficacy
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Marqueurs biologiques tumoraux
/
Protéine p53 suppresseur de tumeur
/
Tumeurs du côlon
/
Fluorouracil
/
Mutation
Type d'étude:
Clinical_trials
/
Guideline
/
Observational_studies
/
Prognostic_studies
Limites:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
EBioMedicine
Année:
2015
Type de document:
Article
Pays d'affiliation:
Autriche